首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment.
【24h】

Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment.

机译:特发性腹膜后纤维化:发病机理及治疗方法的综述。

获取原文
获取原文并翻译 | 示例
           

摘要

Idiopathic retroperitoneal fibrosis (IRPF) is an increasingly recognized syndrome. The development of inflammation and fibrosis in the retroperitoneum most often results in a periaortic mass on computed tomography or magnetic resonance imaging that causes pain and constitutional symptoms. Its organ involvement results in urinary tract obstruction, bowel dysfunction, and venous compression with leg swelling, or thrombosis. The syndrome appears autoimmune in nature, but has no specific immunologic markers. However, nonspecific inflammatory indicators, such as sedimentation rate and C-reactive protein level, reflect disease activity and therapeutic response. Retroperitoneal fibrosis also can arise secondary to inflammatory, infectious, or malignant disease in retroperitoneal organs, in which case treatment is directed at the primary process. However, in patients with IRPF, initial treatment of the local mechanical complications must be followed by medical therapy with corticosteroids or, more recently, the addition of steroid-sparing agents. Although there are no controlled therapeutic trials, a number of reports with as few as 3 or as many as 28 cases describe sustained and effective steroid-sparing treatment with cyclophosphamide, azathioprine or colchicine, or such newer agents as mycophenolate mofetil or tamoxifen. Overall, IRPF responds to corticosteroid therapy initially but recurs without prolonged treatment. Sustained remission can be attained with steroid-sparing treatment. Kidney function can be preserved, and local organ dysfunction can remit for periods of 10 years or more. Although not randomized or controlled, the evidence convincingly supports a combination of initial surgical or urological intervention, along with early corticosteroid therapy for up to 6 months followed by either mycophenolate or tamoxifen for 1 to 3 years. What was previously believed to be an uncommon and challenging syndrome can be treated successfully when recognized by its characteristic presentation.
机译:特发性腹膜后纤维化(IRPF)是一种日益被认可的综合征。腹膜后炎症和纤维化的发展通常会导致计算机断层扫描或磁共振成像上的腹主动脉包块,从而引起疼痛和体质症状。它的器官受累会导致尿路阻塞,肠功能障碍和静脉压迫,并伴有腿部肿胀或血栓形成。该综合征本质上表现为自身免疫,但没有特异性免疫标志。但是,非特异性炎症指标,例如沉降速率和C反应蛋白水平,反映了疾病的活动性和治疗反应。腹膜后纤维化也可继发于腹膜后器官的炎性,感染性或恶性疾病,在这种情况下,治疗应针对主要过程。但是,对于IRPF患者,必须先对局部机械并发症进行初步治疗,然后再进行皮质类固醇药物治疗,或者最近添加类固醇保护剂。尽管没有受控的治疗试验,但有至少3例或多达28例的许多报道描述了用环磷酰胺,硫唑嘌呤或秋水仙碱或新型药物如霉酚酸酯或他莫昔芬持续有效的类固醇激素治疗。总体而言,IRPF最初对皮质类固醇激素治疗有反应,但无需长期治疗即可复发。保留类固醇的治疗可使病情持续缓解。肾脏功能可以保留,局部器官功能障碍可以缓解10年或更长时间。尽管没有被随机或控制,但有说服力的证据有力地支持了最初的外科手术或泌尿外科干预,以及长达6个月的早期皮质类固醇激素疗法,然后是霉酚酸酯或他莫昔芬1-3年。以前被认为是罕见且具有挑战性的综合症,只要其特征性表现得到认可,就可以成功治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号